However, when the relative expression of GRP78 to SPARC was examined, low expression of GRP78/SPARC was associated with a significantly better prognosis: the median disease-free survival of 5.50 months (95% CI: 3.59, 7.45) in comparison with those whose CRC had high GRP78/SPARC expression, median disease-free survival of 3.71 (95% CI: 2.93, 4.30; p-value = 0.01) (Fig. 4b). Here, SPARC is linked to colorectal carcinoma.